Context Therapeutics (CNTX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

CNTX · Stock Price

USD 2.33+1.55 (+198.34%)

Market Cap: $210.9M

Historical price data

Overview

Context Therapeutics is a clinical-stage biopharmaceutical company with a mission to transform cancer care by developing next-generation T cell engager (TCE) bispecific antibodies for solid tumors. The company has successfully pivoted and built a pipeline of three novel, clinical-stage TCE candidates, each featuring distinct engineering approaches to enhance efficacy and safety. Its strategy focuses on rapidly advancing these assets through early clinical trials to demonstrate proof-of-concept in difficult-to-treat cancers.

OncologySolid Tumors

Technology Platform

Next-generation T cell engager (TCE) bispecific antibody platform featuring advanced protein engineering such as pH-dependent binding and avidity/affinity tuning to enhance tumor selectivity and safety in solid tumors.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
Onapristone + Fulvestrant	ER-positive Breast Cancer	Phase 2
Onapristone ER + Onapristone ER + Anastrozole	Granulosa Cell Ovarian Cancer	Phase 2
Extended-release Onapristone + Anastrozole	Refractory Endometrial Adenocarcinoma	Phase 2
Elacestrant + Onapristone	Breast Cancer	Phase 1/2
Elacestrant + Onapristone	Breast Cancer	Phase 1/2

Opportunities

The company has multiple shots on goal with three novel, clinically-differentiated TCEs entering Phase 1 trials.

Success in any program, particularly in a large solid tumor indication like ovarian or pancreatic cancer, could unlock significant value and partnership potential.

The strategic focus on next-generation engineering to improve safety addresses a key bottleneck in solid tumor TCE development.

Risk Factors

High clinical risk as all assets are in early-stage trials with unproven novel engineering features.

The company faces significant financial risk with a limited cash runway and a low stock price, making future dilutive financing likely.

Intense competition in the solid tumor TCE space from larger, better-funded entities poses a threat.

Competitive Landscape

Context faces target-specific competition from companies like BioNTech (CLDN6 CAR-T) and Astellas/Seagen (Nectin-4 ADC), and broader platform competition from numerous biopharma firms developing solid tumor TCEs. Its differentiation hinges on demonstrating superior safety and efficacy through its proprietary avidity, affinity, and pH-dependent engineering approaches.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →